MiNK Therapeutics Inc. (INKT)
| Bid | 7.97 |
| Market Cap | 33.69M |
| Revenue (ttm) | -1.17B |
| Net Income (ttm) | -1.38M |
| EPS (ttm) | -3.7 |
| PE Ratio (ttm) | -2.3 |
| Forward PE | -2.04 |
| Analyst | Strong Buy |
| Ask | 9.34 |
| Volume | 10,791 |
| Avg. Volume (20D) | 35,260 |
| Open | 8.69 |
| Previous Close | 8.95 |
| Day's Range | 8.38 - 8.81 |
| 52-Week Range | 4.56 - 19.00 |
| Beta | 0.17 |
About INKT
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was former...
Analyst Forecast
According to 2 analyst ratings, the average rating for INKT stock is "Strong Buy." The 12-month stock price forecast is $19.5, which is an increase of 129.41% from the latest price.
3 months ago · seekingalpha.com
MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call TranscriptMiNK Therapeutics, Inc. (NASDAQ:INKT ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Alexa Buffa - Corporate Communications Jennifer Buell - President and Chief Ex...